News & Publications

Stanford Cancer Institute News

  • ASH President-Elect: A Look Back on the Path That Led Him Here

    In 2023, Negrin was elected president of the American Society of Hematology (ASH) after over 25 years of service to the organization.

  • CAR-T Cell Therapy in Solid Tumors

    CAR-T therapy has shown a great benefit in patients with hematologic and lymphatic cancers. However, applying the therapy to solid tumors has proven to be challenging. One of the barriers is T cell exhaustion, where the CAR-T cell becomes dysfunctional.

  • Meryl's Story

    Meryl Selig has had a unique experience at the Stanford Cancer Institute (SCI). She began as a patient volunteer in 2009 before being diagnosed with cancer and becoming a patient. She became one of the first patients to receive a novel chimeric antigen receptor (CAR-T) cell therapy when she enrolled in a phase-one clinical trial in 2023.

  • The Stanford Cancer Institute Early Drug Development program awarded for increasing clinical trial access

    The Stanford Cancer Institute Early Drug Development (EDD) program brings in early-phase clinical trials so cancer patients can have access to innovative treatments that could provide a therapeutic benefit.

Stanford Medicine News: Cancer


Scope Blog


Stanford University News: Cancer

Media Relations